Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.63 |
| ▸ | CTSK | P43235 | 7/20 | 0.62 |
| ▸ | CTSB | P07858 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 3/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768345 | 1.00 | CTSL (0.63) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL7796791 | 0.86 | CTSL (0.67) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL7330463 | 0.84 | CTSL (0.67) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL7135056 | 0.84 | CTSL (0.61) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL7764593 | 0.83 | CTSL (0.65) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL7304278 | 0.82 | CTSL (0.68) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL21367481 | 0.82 | CTSK (0.60) | CTSLCTSKCTSBCTSS | |
| SCHEMBL7304260 | 0.82 | CTSL (0.68) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL25406813 | 0.82 | CTSK (0.77) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL4872585 | 0.82 | CTSK (0.77) | CTSLCTSKCTSBCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1159260-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000055124-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CTSL 14/4885CTSK 29/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.